AbbVie to acquire Capstan Therapeutics for $2.1 billion
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
mRNA-1010 demonstrated superior relative vaccine efficacy
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
Granules India receives 1 observation from USFDA for Chantilly facility
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
Subscribe To Our Newsletter & Stay Updated